Jean M. Nappi

Title
InstitutionMedical University of South Carolina
DepartmentCOP Clinical Pharmacy and Outcome Sciences - MUSC Campus
AddressP.O. Box MSC132
QE213D
43 Sabin St.
Phone843-792-7628
Fax843-792-3759
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    1995Presidents Award, American College of Clinical Pharmacy
    2002Clinical Practice Award, American College of Clinical Pharmacy
    2004National Leadership Award, Phi Lambda Sigma
    2006Education Award, American College of Clinical Pharmacy
    2012Distinguished Pharmacy Educator Award, American Association of Colleges of Pharmacy

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Weeda ER, Hayes GL, Gaspar EA, Thomas RJ, Nappi JM, Weant KA. Advice Provided by a Pharmacy Residency Research Committee. Ann Pharmacother. 2021 May 12; 10600280211017332. PMID: 33980077.
      Citations:    
    2. Bradley D, Nappi J. Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center. Pharm Pract (Granada). 2019 Jan-Mar; 17(1):1376. PMID: 31015875.
      Citations:    
    3. Jackevicius CA, Page RL, Buckley LF, Jennings DL, Nappi JM, Smith AJ. Key Articles and Guidelines in the Management of Heart Failure: 2018 Update. J Pharm Pract. 2019 Feb; 32(1):77-92. PMID: 30798691.
      Citations:    
    4. Thompson AN, McKinzie BP, Haney JS, Nappi JM, Pilch N. Pharmacy residency training measured through a standardized knowledge test. Am J Health Syst Pharm. 2016 Dec 15; 73(24):2095-2098. PMID: 27919878.
      Citations:    
    5. Thompson AN, Nappi J, McKinzie B, Haney J, Pilch N. Making the Transition from Student to Resident: A Method to Individualize a PGY1 Program. Pharmacy (Basel). 2016 Oct 20; 4(4). PMID: 28970404.
      Citations:    
    6. Nappi JM, Sieg A, Hassig TB, Wahlquist AE. Impact of Norepinephrine Shortage on Outcomes in Patients with Septic Shock. Res Rev J Hosp Clin Pharm. 2016 May; 2(2):87-91. PMID: 28804796.
      Citations:    
    7. Cheng JW, Colucci V, Howard PA, Nappi JM, Spinler SA. Vorapaxar in atherosclerotic disease management. Ann Pharmacother. 2015 May; 49(5):599-606. PMID: 25680760.
      Citations:    
    8. Nappi J, DeVane CL. In her own words: Jean Nappi, ACCP President, 1994-1995. Pharmacotherapy. 2015 Jan; 35(1):4-7. PMID: 25630409.
      Citations:    
    9. Wiggins BS, Nappi J, Fortier CR, Taber DJ. Cardiovascular Drug Shortages: Predominant Etiologies, Clinical Implications, and Management Strategies. Ann Pharmacother. 2014 Sep; 48(9):1177-1186. PMID: 24915735.
      Citations:    
    10. Nappi JM. An academician preparation program for pharmacy residents. Am J Pharm Educ. 2013 Jun 12; 77(5):101. PMID: 23788812.
      Citations:    
    11. Nappi JM. A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide. Pharm Pract (Granada). 2013 Jan; 11(1):44-50. PMID: 24155849.
      Citations:    
    12. Ball S, Drayton S, Robert S, Hahn N, Nappi J, Egede LE, Moran WP, Dickson M, Mauldin PD, Malcolm R. Physician acceptance of academic detailing for schizophrenia among South Carolina Medicaid providers. J S C Med Assoc. 2012 Aug; 108(4):100-2. PMID: 23270103.
      Citations:    
    13. Chisholm-Burns MA, Spivey CA, Billheimer D, Schlesselman LS, Flowers SK, Hammer D, Engle JP, Nappi JM, Pasko MT, Ross LA, Sorofman B, Rodrigues HA, Vaillancourt AM. Multi-institutional study of women and underrepresented minority faculty members in academic pharmacy. Am J Pharm Educ. 2012 Feb 10; 76(1):7. PMID: 22412206.
      Citations:    
    14. Cogdill B, Nappi JM. Assessment of prescribers' knowledge of the cost of medications. Ann Pharmacother. 2012 Feb; 46(2):200-7. PMID: 22318929.
      Citations:    
    15. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011 Dec; 55(12):5475-9. PMID: 21947388.
      Citations:    
    16. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011; 7:353-63. PMID: 21731887.
      Citations:    
    17. Blue AV, Charles L, Howell D, Koutalos Y, Mitcham M, Nappi J, Zoller J. Introducing students to patient safety through an online interprofessional course. Adv Med Educ Pract. 2010; 1:107-14. PMID: 23745069.
      Citations:    
    18. Bosso JA, Chisholm-Burns M, Nappi J, Gubbins PO, Ross LA. Benchmarking in academic pharmacy departments. Am J Pharm Educ. 2010 Oct 11; 74(8):140. PMID: 21179251.
      Citations:    
    19. Dehoney SB, Dickerson LM, Nappi JM. Comparison of chronic systolic heart failure guideline adherence for two ambulatory clinics. Pharm Pract (Granada). 2010 Jan; 8(1):56-61. PMID: 25152794.
      Citations:    
    20. Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010 Mar; 16(3):188-93. PMID: 20206891.
      Citations:    
    21. Starr JA, Nappi JM. A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritide. Pharm Pract (Granada). 2009 Jul; 7(3):175-80. PMID: 25143796.
      Citations:    
    22. Pallares MJ, Powers ER, Zwerner PL, Fowler A, Reeves R, Nappi JM. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother. 2009 Feb; 43(2):259-67. PMID: 19193589.
      Citations:    
    23. Nappi J, Haase K, Kessels A, Fink J. What is a pharmacotherapy residency? Benefits of a 24-month program. Pharmacotherapy. 2008 Jul; 28(7):819-20. PMID: 18576896.
      Citations:    
    24. Nappi J. Benefits and limitations of current antiplatelet therapies. Am J Health Syst Pharm. 2008 Jul 01; 65(13 Suppl 5):S5-10; quiz S16-8. PMID: 18574022.
      Citations:    
    25. Stelts S, Taylor MH, Nappi J, Van Bakel AB. Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis. Ann Pharmacother. 2008 Jun; 42(6):904-5. PMID: 18430794.
      Citations:    
    26. Choy CK, Rodgers JE, Nappi JM, Haines ST. Type 2 diabetes mellitus and heart failure. Pharmacotherapy. 2008 Feb; 28(2):170-92. PMID: 18225964.
      Citations:    
    27. Choy CK, Spencer AP, Nappi JM. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment. Pharmacotherapy. 2007 May; 27(5):707-14. PMID: 17461706.
      Citations:    
    28. Murphy JE, Saseen JJ, Nappi J, Bosso JA. Comments on draft of work force document. Am J Health Syst Pharm. 2006 Sep 01; 63(17):1592. PMID: 16914627.
      Citations:    
    29. Sorensen TD, Anderson W, Delafuente JC, Diamond L, Nappi J, Pieper J. Professional practice plans: recommendations from the 2005 Council of Faculties-Council of Deans Task Force. Am J Pharm Educ. 2006 Jun 15; 70(3):S03. PMID: 17136167.
      Citations:    
    30. Murphy JE, Nappi JM, Bosso JA, Saseen JJ, Hemstreet BA, Halloran MA, Spinler SA, Welty TE, Dobesh PP, Chan LN, Garvin CG, Grunwald PE, Kamper CA, Sanoski CA, Witkowski PL. American College of Clinical Pharmacy's vision of the future: postgraduate pharmacy residency training as a prerequisite for direct patient care practice. Pharmacotherapy. 2006 May; 26(5):722-33. PMID: 16637798.
      Citations:    
    31. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr; 26(4):461-8. PMID: 16553503.
      Citations:    
    32. Schwiesow SJ, Nappi JM, Ragucci KR. Assessment of compliance with lipid guidelines in an academic medical center. Ann Pharmacother. 2006 Jan; 40(1):27-31. PMID: 16352778.
      Citations:    
    33. Nappi JM. The role of B-type natriuretic peptide in heart failure. Crit Care Nurs Clin North Am. 2003 Dec; 15(4):461-5. PMID: 14717391.
      Citations:    
    34. Davis KL, Nappi JM. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther. 2003 Nov; 25(11):2647-68. PMID: 14693297.
      Citations:    
    35. Nappi J. Anemia in patients with coronary artery disease. Am J Health Syst Pharm. 2003 Jul 15; 60(14 Suppl 3):S4-8. PMID: 12908376.
      Citations:    
    36. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2003 Jul-Aug; 37(7-8):1055-62. PMID: 12841819.
      Citations:    
    37. Crouch MA, Nappi JM, Cheang KI. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother. 2003 Jun; 37(6):860-75. PMID: 12773077.
      Citations:    
    38. Talbert RL, Spinier SA, Nappi JM, Bottorff MB. Combination antiplatelet therapy: implications for pharmacists. J Am Pharm Assoc (Wash). 2002 Nov-Dec; 42(6):880-3. PMID: 12482014.
      Citations:    
    39. Lewin JJ, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002 Oct; 36(10):1546-9. PMID: 12243603.
      Citations:    
    40. Talbert RL, Spinler SA, Nappi JM, Bottorff MB. Combination antiplatelet therapy: implications for pharmacists. Pharmacotherapy. 2002 Oct; 22(10):1211-5. PMID: 12389871.
      Citations:    
    41. Nappi J, Talbert R. Dual antiplatelet therapy for prevention of recurrent ischemic events. Am J Health Syst Pharm. 2002 Sep 15; 59(18):1723-35. PMID: 12298110.
      Citations:    
    42. Nappi J. The biology of thrombin in acute coronary syndromes. Pharmacotherapy. 2002 Jun; 22(6 Pt 2):90S-96S. PMID: 12064570.
      Citations:    
    43. Nappi J. Heparin, bivalirudin, and reduction of complications during percutaneous coronary intervention. Pharmacotherapy. 2002 Jun; 22(6 Pt 2):89S. PMID: 21910658.
      Citations:    
    44. Kalus JS, Nappi JM. Role of race in the pharmacotherapy of heart failure. Ann Pharmacother. 2002 Mar; 36(3):471-8. PMID: 11895062.
      Citations:    
    45. Turcasso NM, Nappi JM. Tenecteplase for treatment of acute myocardial infarction. Ann Pharmacother. 2001 Oct; 35(10):1233-40. PMID: 11675853.
      Citations:    
    46. Spinler SA, Hilleman DE, Cheng JW, Howard PA, Mauro VF, Lopez LM, Munger MA, Gardner SF, Nappi JM. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. Ann Pharmacother. 2001 May; 35(5):589-617. PMID: 11346067.
      Citations:    
    47. Wiggins BS, Wittkowsky AK, Nappi JM. Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes. Pharmacotherapy. 2001 Mar; 21(3):320-37. PMID: 11253856.
      Citations:    
    48. Bell DM, Nappi J. Myocardial infarction in women: a critical appraisal of gender differences in outcomes. Pharmacotherapy. 2000 Sep; 20(9):1034-44. PMID: 10999494.
      Citations:    
    49. Lenhart SE, Nappi JM. Vitamins for the management of cardiovascular disease: a simple solution to a complex problem? Pharmacotherapy. 1999 Dec; 19(12):1400-14. PMID: 10600089.
      Citations:    
    50. Liston H, Bennett L, Usher B, Nappi J. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med. 1999 Mar 08; 159(5):511-3. PMID: 10074961.
      Citations:    
    51. Nolan PE, Nappi J, Pollak PT. Clinical efficacy of amiodarone. Pharmacotherapy. 1998 Nov-Dec; 18(6 Pt 2):127S-137S. PMID: 9855345.
      Citations:    
    52. Crouch MA, Nappi JM. Adjunctive intracoronary thrombolysis in complicated coronary angioplasty. Ann Pharmacother. 1997 Oct; 31(10):1244-6. PMID: 9337450.
      Citations:    
    53. Cooke CE, Sklar GE, Nappi JM. Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother. 1996 Apr; 30(4):364-6. PMID: 8729890.
      Citations:    
    54. Nappi JM, McCollam PL. Sotalol: a breakthrough antiarrhythmic? Ann Pharmacother. 1993 Nov; 27(11):1359-68. PMID: 8286812.
      Citations:    
    55. McCollam PL, Nappi JM. Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place? Ann Pharmacother. 1993 Jun; 27(6):736-41. PMID: 8329797.
      Citations:    
    56. Pool PE, Nappi JM, Weber MA. Antihypertensive monotherapy with tablet (prompt-release) diltiazem: multicenter controlled trials. Cardiovasc Drugs Ther. 1990 Aug; 4(4):1089-96. PMID: 2083193.
      Citations:    
    57. Pool PE, Herron JM, Rosenblatt S, Reeves RL, Nappi JM, Staker LV, Dipette DJ, Evans RR. Sustained-release diltiazem: duration of antihypertensive effect. J Clin Pharmacol. 1989 Jun; 29(6):533-7. PMID: 2666454.
      Citations:    
    58. Pool PE, Herron JM, Rosenblatt S, Reeves RL, Nappi JM, Staker LV, DiPette DJ, Evans RR. Metabolic effects of antihypertensive therapy with a calcium antagonist. Am J Cardiol. 1988 Oct 05; 62(11):109G-113G. PMID: 3051991.
      Citations:    
    59. Nappi JM, Bosso JA. Clinical pharmacy and clinical research. Drug Intell Clin Pharm. 1988 Oct; 22(10):804-6. PMID: 3068040.
      Citations:    
    60. Kralios AC, Nappi JM, Tsagaris TJ, Kralios FA, Kuida H. Paradoxical increase of ventricular fibrillation threshold in response to coronary sinus obstruction. Am Heart J. 1988 Feb; 115(2):334-40. PMID: 3341168.
      Citations:    
    61. Hampton EM, Anastasiou-Nana MI, Nanas JN, Nappi JM, Capuzzi DM, Anderson JL. The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients. J Clin Pharmacol. 1987 Dec; 27(12):951-6. PMID: 3437067.
      Citations:    
    62. Hampton EM, Anderson JL, Lutz JR, Nappi JM. Initial and long-term outpatient experience with pirmenol for control of ventricular arrhythmias. Eur J Clin Pharmacol. 1986; 31(1):15-22. PMID: 3780822.
      Citations:    
    63. Nappi JM, Anderson JL. Flecainide: a new prototype antiarrhythmic agent. Pharmacotherapy. 1985 Jul-Aug; 5(4):209-21. PMID: 3898035.
      Citations:    
    64. Anderson JL, Lutz JR, Nappi JM. Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study. Am J Cardiol. 1984 Feb 01; 53(4):522-7. PMID: 6198894.
      Citations:    
    65. Anderson JL, Lutz JR, Sanders SW, Nappi JM. Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: a controlled comparison with lidocaine. J Cardiovasc Pharmacol. 1983 Mar-Apr; 5(2):213-20. PMID: 6188892.
      Citations:    
    66. Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, Hoffman SF, Wallace JE, Lalka D, McNay JL. Individualization of phenytoin dosage regimens. Clin Pharmacol Ther. 1977 Mar; 21(3):287-93. PMID: 837647.
      Citations:    
    Nappi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (298)
    Explore
    _
    Co-Authors (19)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _